Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy

Wei Li; Fenglei Wu; Shaolin Zhao; Peiqin Shi; Shengjun Wang; Dawei Cui

doi:10.1016/j.cytogfr.2022.07.004

journal article Open Access Oct 01, 2022

Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy

Wei Li

Fenglei Wu Shaolin Zhao Peiqin Shi

Shengjun Wang

Dawei Cui

Cytokine & Growth Factor Reviews Vol. 67 pp. 49-57 · Elsevier BV

View at Publisher Save 10.1016/j.cytogfr.2022.07.004

Topics

No keywords indexed for this article. Browse by subject →

References

101

[1]

Wei "Fundamental mechanisms of immune checkpoint blockade therapy" Cancer Discov. (2018) 10.1158/2159-8290.cd-18-0367

[2]

Okazaki "PD-1 and PD-1 ligands: from discovery to clinical application" Int. Immunol. (2007) 10.1093/intimm/dxm057

[3]

Liechtenstein "PD-L1/PD-1 co-stimulation, a brake for T cell activation and a T cell differentiation signal" J. Clin. Cell Immunol. (2012)

[4]

Jiang "PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations" Hum. Vaccin. Immunother. (2019) 10.1080/21645515.2019.1571892

[5]

Xia "PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions" Oncologist (2019) 10.1634/theoncologist.2019-io-s1-s05

[6]

Kim "Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer" Nat. Med. (2018) 10.1038/s41591-018-0101-z

[7]

Emens "Breast cancer immunotherapy: facts and hopes" Clin. Cancer Res. (2018) 10.1158/1078-0432.ccr-16-3001

[8]

Baxi "Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis" BMJ (2018) 10.1136/bmj.k793

[9]

Brahmer "Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer" N. Engl. J. Med. (2015) 10.1056/nejmoa1504627

[10]

Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis

Jue Zhu, Lifeng Yan, Qiming Wang

Journal of Ovarian Research 2021 10.1186/s13048-021-00862-5

[11]

Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade

Natalija Budimir, Graham D. Thomas, Joseph S. Dolina et al.

Cancer Immunology Research 2022 10.1158/2326-6066.cir-21-0515

[12]

NK cells and ILCs in tumor immunotherapy

Simona Sivori, Daniela Pende, Linda Quatrini et al.

Molecular Aspects of Medicine 2021 10.1016/j.mam.2020.100870

[13]

Trefny "PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade" Cancer Immunol. Immunother. (2020) 10.1007/s00262-020-02558-z

[14]

Sun "Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis" Transl. Oncol. (2020) 10.1016/j.tranon.2020.100825

[15]

Luz-Crawford "Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway" PLOS One (2012) 10.1371/journal.pone.0045272

[16]

Chen "Insluin and epithelial growth factor (EGF) promote programmed death ligand 1 (PD-L1) production and transport in colon cancer stem cells" BMC Cancer (2019) 10.1186/s12885-019-5364-3

[17]

Gordon "PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity" Nature (2017) 10.1038/nature22396

[18]

Jiang "TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis" J. Clin. Investig. (2021) 10.1172/jci139434

[19]

Lopez-Yrigoyen "Macrophage targeting in cancer" Ann. N. Y. Acad. Sci. (2021) 10.1111/nyas.14377

[20]

Wu "Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment" Front. Immunol. (2020) 10.3389/fimmu.2020.01731

[21]

Hartley "Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation" Cancer Immunol. Res. (2018) 10.1158/2326-6066.cir-17-0537

[22]

Chen "ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation" Theranostics (2021) 10.7150/thno.52435

[23]

Yagi "Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer" Eur. J. Cancer (2019) 10.1016/j.ejca.2019.01.018

[24]

Laviron "Ontogeny of tumor-associated macrophages" Front. Immunol. (2019) 10.3389/fimmu.2019.01799

[25]

Macrophage Polarization States in the Tumor Microenvironment

Ava J. Boutilier, Sherine F. Elsawa

International Journal of Molecular Sciences 2021 10.3390/ijms22136995

[26]

PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages

Zhiyuan Zhu, Hongbo Zhang, Baodong Chen et al.

Frontiers in Immunology 2020 10.3389/fimmu.2020.588552

[27]

Yang "CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis" Mol. Cancer (2020) 10.1186/s12943-020-01165-x

[28]

Tan "Inhibition of Rspo-Lgr4 facilitates checkpoint blockade therapy by switching macrophage polarization" Cancer Res. (2018) 10.1158/0008-5472.can-18-0152

[29]

Liu "Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization" Mol. Ther. (2021) 10.1016/j.ymthe.2021.03.013

[30]

Nadella "Emerging neo adjuvants for harnessing therapeutic potential of M1 tumor associated macrophages (TAM) against solid tumors: enusage of plasticity" Ann. Transl. Med. (2020) 10.21037/atm-20-695

[31]

Xie "PD-1/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas" Curr. Hematol. Malign. Rep. (2020) 10.1007/s11899-020-00589-y

[32]

Masuda "Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression" J. Cancer Res. Clin. Oncol. (2021) 10.1007/s00432-020-03329-0

[33]

Olson "Pembrolizumab plus ipilimumab following anti-PD-1/L1 failure in melanoma" J. Clin. Oncol. (2021) 10.1200/jco.21.00079

[34]

Nowicki "Mechanisms of resistance to PD-1 and PD-L1 blockade" Cancer J. (2018) 10.1097/ppo.0000000000000303

[35]

Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion

David H. Peng, Bertha Leticia Rodriguez, Lixia Diao et al.

Nature Communications 2020 10.1038/s41467-020-18298-8

[36]

Santoni "Triple negative breast cancer: key role of tumor-associated macrophages in regulating the activity of anti-PD-1/PD-L1 agents" Biochim. Biophys. Acta Rev. Cancer (2018) 10.1016/j.bbcan.2017.10.007

[37]

Cai "The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer" J. Cancer Res. Clin. Oncol. (2019) 10.1007/s00432-019-02879-2

[38]

Peng "PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade" Nat. Commun. (2020) 10.1038/s41467-020-18570-x

[39]

Dong "The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector" Cancer Discov. (2019) 10.1158/2159-8290.cd-18-1259

[40]

Wang "Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway" Gut (2017) 10.1136/gutjnl-2016-313075

[41]

Zhang "IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma" J. Immunother. Cancer (2020) 10.1136/jitc-2019-000285

[42]

Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8+ T cell exclusion

Wenli Fang, Ting Zhou, He Shi et al.

Journal of Experimental & Clinical Cancer Rese... 2021 10.1186/s13046-020-01786-6

[43]

Liu "Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy" Clin. Cancer Res. (2020) 10.1158/1078-0432.ccr-19-1040

[44]

Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma

Emilien Loeuillard, Jingchun Yang, EeeLN Buckarma et al.

Journal of Clinical Investigation 2020 10.1172/jci137110

[45]

McCord "PD-L1 and tumor-associated macrophages in De Novo DLBCL" Blood Adv. (2019) 10.1182/bloodadvances.2018020602

[46]

COX2/mPGES1/PGE 2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells

Victor Prima, Lyudmila N. Kaliberova, Sergey Kaliberov et al.

Proceedings of the National Academy of Sciences 2017 10.1073/pnas.1612920114

[47]

Cantero-Cid "PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?" BMC Cancer (2018) 10.1186/s12885-018-4853-0

[48]

Miyasato "The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma" J. Clin. Exp. Hematop (2018) 10.3960/jslrt.18001

[49]

Hartley "Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-alpha" Cancer Immunol. Immunother. (2017) 10.1007/s00262-017-1955-5

[50]

Wen "Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1" J. Immunother. Cancer (2018) 10.1186/s40425-018-0452-5

Showing 50 of 101 references

Metrics

142

Citations

101

References

Details

Published: Oct 01, 2022
Vol/Issue: 67
Pages: 49-57
License: View

Authors

W

Wei Li

North University of China

Cite This Article

Wei Li, Fenglei Wu, Shaolin Zhao, et al. (2022). Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy. Cytokine & Growth Factor Reviews, 67, 49-57. https://doi.org/10.1016/j.cytogfr.2022.07.004

Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy

You May Also Like